Registrieren
E-Mail:
Passwort:
Ich akzeptiere die
Nutzungsbedingungen
Registrieren
Registierung erfolgt in Kürze...
query
ai
Login
Registrieren
Infos
Werben auf fleebs.com
Seite indizieren lassen
Einstellungen
Datenschutz
Nutzungsbedingungen
Impressum
Details werden geladen...
https://www.statnews.com/2026/06/01/asco-news-day-4-merkel-cell-carcinoma-glp1s-grail/
Teilen bei
Facebook
Teilen bei
Twitter
Teilen bei
Pinterest
Per Mail empfehlen
At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
Here is some of what you may have missed from the world's largest cancer research meeting.
Ähnliche Seiten
An ASCO preview: What to watch for at cancer research's big meeting | STAT
https://www.statnews.com/2026/05/28/asco-preview-cancer-meeting/
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
https://www.statnews.com/2026/05/29/asco-news-day-1-multiple-myeloma-bristol-lung-cancer-pfizer/
At the world’s largest cancer research meeting, data briefly took a backseat to grief
https://www.statnews.com/2026/06/01/cancer-oncologists-grief-asco-2026/
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmark-at-the-2026-asco-annual-meeting/2349737
Doctors may have found an easier way to treat prostate cancer — could become new ‘standard of care’
https://nypost.com/2026/05/17/health/doctors-may-have-found-an-easier-way-to-treat-prostate-cancer/
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752
Please enable JavaScript to continue using this application.